An observational study in Twins and Metabolic Syndrome, sponsored by Poznan University of Medical Sciences. Recruiting at 1 site in Poland. Open to participants aged 15 Years to 44 Years. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Poznan University of Medical Sciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Metabolic Syndrome with a site in Poland — 10 open to participants now, 13 under way, 1 of them phase 3. Metabolic Syndrome · Poland.
Among the 31 studies in Metabolic Syndrome with a site in Poland, this one is the 2nd largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2025, is one of 12 observational ones, reaches primary completion later than 12 of the 12 other live ones, and was the 25th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →10 of the 31 studies in Metabolic Syndrome with a site in Poland are open now. Recruiting first, the newest first:
University of Applied Sciences in Nowy Targ · Sites in Poland
Ages 18–35 · Women only · Healthy volunteers
Jagiellonian University · Sites in Poland
Ages 18–45 · Women only · Healthy volunteers
Jagiellonian University · Sites in Poland
Ages 18–45 · Women only · Healthy volunteers
Jagiellonian University · Sites in Poland
Ages 18–45 · Women only · Healthy volunteers
Collegium Medicum w Bydgoszczy · Sites in Poland
Ages 18–85
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 15 Years to 44 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 196 across 497 observational studies indexed under Metabolic Syndrome.
Median enrollment 96 across the 19 interventional studies, 143 across the 12 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 31 have an industry lead sponsor. The 10 most frequent:
Poznan University of Medical Sciences is the lead sponsor of 152 studies on the registry; 42 are open to participants now.
Poznan University of Medical Sciences has 4 studies filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Metabolic Syndrome with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04634591Medical University of BialystokThe Bialystok Bariatric Surgery Study | 2026-12-31 |
| NCT07917364University of Applied Sciences in Nowy TargAsprosin and miRNA Expression in Young Women With Metabolic Syndrome | 2027-03 |
| NCT07358533Pomeranian Medical University SzczecinMetabolic Obesity in Normal Weight (MONW): Diagnostic Markers Stud | 2027-05 |
| NCT07793487Warsaw University of Life SciencesApplications of a Functional Dairy Product in Diet Therapy | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Metabolic Syndrome with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Over a 5-year follow-up period, we aim to conduct a study among twins aged 15-44 years from the Polish population with the following objectives:
The study population comprises Polish twin individuals aged 15-44 years, who have provided informed consent, have a living co-twin, and present a positive family history (first- or second-degree relatives) of metabolic syndrome, its related comorbidities, or common complications.
Inclusion Criteria
1. Age between 15 and 44 years. 2. Provision of to participate in the study. 3. Twin with a living co-twin. 4. Positive family history in first- and second-degree relatives of metabolic syndrome (MS), associated diseases, or the most common complications of the syndrome.
________________________________________ Exclusion Criteria
Permanent exclusion criteria:
Temporary exclusion criteria (after resolution, the volunteer may be enrolled):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Educational intervention based on a protocol specifically developed for the TWINS.PL cohort, aimed at activating and engaging the participant in the intervention process. Intervention group: Phenotypically concordant participants from the TWINS.PL STUDY cohort, randomized to receive an educational intervention designed to actively engage them in modifying selected health-relevant endpoints. Control group: The co-twin of the participant randomized to the intervention arm, serving as the control. 1. TWINS-TWIC HL: Research Question: Does participation in a structured, participant-activating educational intervention program influence health literacy indicators among participants of the TWINS.PL study? Study Design: A randomized controlled trial embedded within a prospective observational twin cohort (TWiC study in a twin cohort). 2. TWINS-TWIC DIET Research Question: Does participation in a structured, participant-activating educational intervention focused on dietary habits influence the
De novo occurrence of metabolic steatosis, hepatic fibrosis, or cirrhosis.
De novo occurrence of metabolic steatosis, hepatic fibrosis, or cirrhosis based on assessment by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) and/or transient elastography.
Time frame: Baseline up to approximately 5 years
Progression of hepatic steatosis or fibrosis to more advanced stages or cirrhosis.
Progression of hepatic steatosis or fibrosis to more advanced stages or cirrhosis, as assessed by magnetic resonance imaging and dynamic elastography, using the following evaluation scales: * The hepatic steatosis grading scale based on magnetic resonance imaging-proton density fat fraction (MRI-PDFF); * The hepatic steatosis grading scale based on dynamic elastography using the Controlled Attenuation Parameter (CAP) technique; * The liver fibrosis grading scale assessed by dynamic elastography using liver stiffness (LS) measurement, according to the METAVIR scoring system
Time frame: Baseline up to approximately 5 years
First-time occurrence of overweight or obesity
Overweight will be defined as a BMI of 25 to \<30 kg/m², and obesity as a BMI of ≥30 kg/m²
Time frame: Baseline to approximately 5 years
First-time occurrence of an increase in visceral adipose tissue
Increase in visceral adipose tissue \>10%, as assessed by DEXA or BIA
Time frame: Baseline to approximately 5 years
First-time occurrence of Prediabetes or type 2 diabetes mellitus (T2DM)
First diagnosis of prediabetes or type 2 diabetes mellitus (T2DM), confirmed by standard laboratory criteria (fasting plasma glucose, HbA1c, or oral glucose tolerance test) in accordance with current ADA/EASD guidelines
Time frame: Baseline to approximately 5 years
The assessment of HOMA-IR
First-time occurrence of HOMA-IR \>5
Time frame: Baseline to approximately 5 years
First-time occurrence of Pancreatic steatosis
Visualization of pancreatic steatosis during abdominal ultrasound and/or MRI-PDFF
Time frame: Baseline to approximately 5 years
First-time occurrence of Hypertension (HTN)
Diagnosis of arterial hypertension according to the ESC/ESH definition
Time frame: Baseline to approximately 5 years
First-time occurrence of Acute coronary syndrome, the need for coronary artery bypass grafting (CABG), any percutaneous coronary intervention (PCI), or detection of regional wall motion abnormalities on echocardiography
All outcome events will be confirmed through review of medical records, including hospitalization reports, procedural documentation, and echocardiographic findings, in accordance with the most recent ESC guidelines on Acute Coronary Syndromes.
Time frame: Baseline to approximately 5 years
First-time occurrence of Systolic heart failure with a reduced left ventricular ejection fraction of less than 45%
Diagnosis of systolic heart failure confirmed by echocardiographic assessment showing a left ventricular ejection fraction (LVEF) \<45%.
Time frame: Baseline to approximately 5 years
First-time occurrence of Atrial fibrillation/flutter
First documented episode of atrial fibrillation (paroxysmal, persistent, or permanent) or atrial flutter, confirmed by ECG or other cardiac monitoring, or the need for pulmonary vein isolation and/or cavotricuspid isthmus ablation.
Time frame: Baseline to approximately 5 years
First-time occurrence of Requirement for angioplasty, stenting, or surgery of the aorta or any other arteries (excluding trauma-related causes)
First requirement for angioplasty, stent placement, or surgical intervention of the aorta or other arteries (excluding trauma-related procedures), confirmed by medical records and procedural documentation.
Time frame: Baseline to approximately 5 years
First-time occurrence of Implantation of a cardiac electronic device
First implantation of a cardiac electronic device (e.g., pacemaker, ICD, or CRT) indicated for sick sinus syndrome, advanced atrioventricular conduction abnormalities, or ischemic heart disease, as confirmed by procedural documentation.
Time frame: Baseline to approximately 5 years
First-time occurrence of Transient ischemic attack (TIA) or ischemic stroke
First documented occurrence of transient ischemic attack (TIA) or ischemic stroke, confirmed by neurological assessment and/or neuroimaging, in accordance with current ESC guidelines.
Time frame: Baseline to approximately 5 years
First-time occurrence of Hashimoto's thyroiditis
Increase of at least one anti-thyroid autoantibody - anti-thyroid peroxidase and/or anti-thyroglobulin, accompanied by typical ultrasound picture suggesting Hashimoto's thyroiditis, namely irregular, decreased echogenicity of thyroid parenchyma, signs of fibrosis and decreased vascularity on Color Doppler examination
Time frame: Baseline to approximately 5 years
First-time occurrence of Focal thyroid lesions detected on ultrasound
Focal thyroid lesions detected on ultrasound (≥1 lesion with a diameter \>5 mm)
Time frame: Baseline to approximately 5 years
First-time occurrence of Adrenal incidentaloma
Adrenal lesion \>10 mm in diameter
Time frame: Baseline to approximately 5 years
First-time occurrence of Malignancy with a known potential association with insulin resistance
e.g., colorectal, thyroid, breast, endometrial, hepatic, pancreatic, renal, gallbladder, esophageal, or ovarian cancer
Time frame: Baseline to approximately 5 years
First-time occurrence of Long COVID-19 syndrome
Defined as persistent (over 12 weeks) symptoms (listed in the questionnaire filled out by the patient), which appeared after COVID-19 infection and their occurrence cannot be explained by other causes
Time frame: Baseline to approximately 5 years
Death from non-accidental causes
The number of deaths from non accidental causes during the observation period
Time frame: Baseline to approximately 5 years
The assessment of HbA1c
First-time occurrence of HbA1c \>5.7%
Time frame: Baseline to approximately 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.
Of 150 non-industry observational studies under Metabolic Syndrome, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 106. This study's planned 36 months is below that.
Counting every sponsor, half of 161 studies reached it within 42 months; a quarter within 18 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Poznan University of Medical Sciences →